Cross-sectional Characterization of Idiopathic Bronchiectasis
NCT01264055
Bronchial Diseases, Bronchiectasis
Stanford, California, United States
View Trial DetailsNCT Number: NCT00724919
To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Miaoli County, Taiwan
This is post-interventional study to follow the acquisition rate of ESBP producing E. coli or K. pneumoniae at the sites involved in a previous interventional study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion
Patients were excluded if they had underlying conditions or diseases that were ultimately fatal within 48 hours
Time frame: 48hours
Time frame: 48hours
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) (A Post-Intervention Surveillance Study)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01264055
Bronchial Diseases, Bronchiectasis
Stanford, California, United States
View Trial DetailsNCT07673484
Allergic Contact Dermatitis, Cicatrix
Küçükçekmece, Istanbul, Turkey (Türkiye)
View Trial DetailsNCT00342589
Bacterial Infections and Mycoses, Infection
Bethesda, Maryland, United States
View Trial DetailsNCT07256405
Bone, Fracture
Marseille, Bouches-du-Rhône, France
View Trial Details